Evidence map›Paper›PMID 39360100›Full record

ArticleCureus2024

Small Intestine Metastasis Leads to the Diagnosis of Thoracic SMARCA4-Deficient Undifferentiated Tumor: A Case Report.

Rei Sanai, Toyoshi Yanagihara, Takato Ikeda, Kaori Koga, Yuki Shundo, Naoki Hamada, Noriyuki Ebi, Hiroyuki Inoue, Yoshihiro Hamada, Makoto Hamasaki and 1 more

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. ThoracicRadiology case reports · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rei SanaiDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Toyoshi YanagiharaDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Takato IkedaDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Kaori KogaDepartment of Pathology, Fukuoka University School of Medicine, Fukuoka, JPN.
Yuki ShundoDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Naoki HamadaDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Noriyuki EbiDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Hiroyuki InoueDepartment of Respiratory Medicine, Fukuoka University Hospital, Fukuoka, JPN.
Yoshihiro HamadaDepartment of Pathology, Fukuoka University School of Medicine, Fukuoka, JPN.
Makoto HamasakiDepartment of Pathology, Fukuoka University School of Medicine, Fukuoka, JPN.
Masaki FujitaDepartment of Respiratory Medicine, Fukuoka University School of Medicine, Fukuoka, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rare and aggressive malignancy characterized by the loss of SMARCA4 protein expression. It typically affects middle-aged male smokers and has a poor prognosis due to its rapid progression and metastatic potential. This case report presents a 73-year-old male diagnosed with a thoracic SMARCA4-UT. Initially diagnosed with stage IVA non-small cell lung cancer, the patient underwent brain tumor resection, radiation, and chemo-immunotherapy. Treatment was halted due to immune-related adverse events. During treatment, a progressing small intestine tumor was discovered, resected, and identified as SMARCA4-UT metastasis through immunohistochemistry, leading to a revised diagnosis of SMARCA4-UT with brain and small intestine metastases. The patient received multimodal treatment, including surgery, radiation, and chemo-immunotherapy. The small intestine metastasis showed resistance to systemic therapy, necessitating surgical intervention. This case highlights the diagnostic challenges and treatment complexities of SMARCA4-UT, emphasizing the importance of comprehensive diagnostic workup and personalized treatment strategies. It demonstrates the potential efficacy of combining systemic therapy with targeted interventions for oligoprogressive disease. The patient's progression-free survival at approximately two years post-diagnosis underscores the need for further research into optimal management strategies for this rare tumor.

Indexed as

brain tumorimmune-checkpoint inhibitor (ici)multimodal approachsmall intestine metastasissmarca4-deficient undifferentiated tumor

Identifiers

PMID39360100
PMCPMC11444843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.